Daiichi Sankyo–Glycotope: antibody-drug conjugates, 201807– license ww excl €na to develop ADC using Daiichi ADC technology with gatipotuzumab

	Period	2018-07-30
	Successor	Daiichi Sankyo–Glycotope: antibody-drug conjugates, 202501 acquisition all IPRs $132.5m for use of gatipotuzumab in ADC DS-3939
	Partner, 1st	Daiichi Sankyo Co., Ltd. (TSE: 4568.JP)
	Group	Daiichi Sankyo (Group)
	Partner, 2nd	Glycotope GmbH
	Group	Glycotope (Group)
	Product	gatipotuzumab (PankoMab-GEX)
	Product 2	antibody-drug conjugates (ADC) technology

Record changed: 2025-03-16

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Daiichi Sankyo (Group)

[1] BioMed X GmbH. (1/14/25). "Press Release: BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy". Heidelberg....
[2] Daiichi Sankyo Co., Ltd.. (1/13/25). "Press Release: Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH". Tokyo & Basking Ridge, NJ....
[3] Daiichi Sankyo Co., Ltd.. (5/22/24). "Press Release: Daiichi Sankyo Establishes Two Research Institutes in the U.S. and EU"....
[4] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
[5] ERS Genomics Ltd.. (1/13/20). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo to Support Internal Research and Development". Dublin....
[6] Immunic, Inc.. (1/8/20). "Press Release: Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]